company background image

ArcticZymes Technologies OB:AZT Stock Report

Last Price


Market Cap







29 Sep, 2022


Company Financials +
AZT fundamental analysis
Snowflake Score
Future Growth6/6
Past Performance2/6
Financial Health6/6

AZT Stock Overview

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing.

ArcticZymes Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ArcticZymes Technologies
Historical stock prices
Current Share Pricekr71.00
52 Week Highkr100.00
52 Week Lowkr64.10
1 Month Change-2.00%
3 Month Change-10.52%
1 Year Change-18.25%
3 Year Change1,517.31%
5 Year Change820.88%
Change since IPO184.00%

Recent News & Updates

May 01
Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results

Here's What Analysts Are Forecasting For ArcticZymes Technologies ASA (OB:AZT) After Its First-Quarter Results

It's been a pretty great week for ArcticZymes Technologies ASA ( OB:AZT ) shareholders, with its shares surging 15% to...

Shareholder Returns

AZTNO BiotechsNO Market

Return vs Industry: AZT exceeded the Norwegian Biotechs industry which returned -59.1% over the past year.

Return vs Market: AZT underperformed the Norwegian Market which returned -4.5% over the past year.

Price Volatility

Is AZT's price volatile compared to industry and market?
AZT volatility
AZT Average Weekly Movement5.3%
Biotechs Industry Average Movement9.5%
Market Average Movement6.7%
10% most volatile stocks in NO Market11.2%
10% least volatile stocks in NO Market3.8%

Stable Share Price: AZT is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: AZT's weekly volatility (5%) has been stable over the past year.

About the Company

1990388Jethro Holter

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally.

ArcticZymes Technologies Fundamentals Summary

How do ArcticZymes Technologies's earnings and revenue compare to its market cap?
AZT fundamental statistics
Market Capkr3.58b
Earnings (TTM)kr51.89m
Revenue (TTM)kr146.79m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AZT income statement (TTM)
Cost of Revenuekr6.57m
Gross Profitkr140.22m
Other Expenseskr88.34m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 27, 2022

Earnings per share (EPS)1.03
Gross Margin95.52%
Net Profit Margin35.35%
Debt/Equity Ratio0%

How did AZT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is AZT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AZT?

Other financial metrics that can be useful for relative valuation.

AZT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue22.9x
Enterprise Value/EBITDA52.3x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does AZT's PE Ratio compare to its peers?

AZT PE Ratio vs Peers
The above table shows the PE ratio for AZT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average31.5x
NORD Norda
A290650 L&C Bio
ORGO Organogenesis Holdings
2160 GNI Group
AZT ArcticZymes Technologies

Price-To-Earnings vs Peers: AZT is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the peer average (31.5x).

Price to Earnings Ratio vs Industry

How does AZT's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Earnings vs Industry: AZT is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the European Biotechs industry average (33.5x)

Price to Earnings Ratio vs Fair Ratio

What is AZT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AZT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio68.9x
Fair PE Ratio47.1x

Price-To-Earnings vs Fair Ratio: AZT is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the estimated Fair Price-To-Earnings Ratio (47.1x).

Share Price vs Fair Value

What is the Fair Price of AZT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AZT (NOK71) is trading below our estimate of fair value (NOK161.58)

Significantly Below Fair Value: AZT is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is ArcticZymes Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score


Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZT's forecast earnings growth (36.4% per year) is above the savings rate (1.1%).

Earnings vs Market: AZT's earnings (36.4% per year) are forecast to grow faster than the Norwegian market (-2.8% per year).

High Growth Earnings: AZT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AZT's revenue (25.7% per year) is forecast to grow faster than the Norwegian market (0.2% per year).

High Growth Revenue: AZT's revenue (25.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AZT's Return on Equity is forecast to be high in 3 years time (26.3%)

Discover growth companies

Past Performance

How has ArcticZymes Technologies performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AZT has high quality earnings.

Growing Profit Margin: AZT's current net profit margins (35.3%) are lower than last year (62.3%).

Past Earnings Growth Analysis

Earnings Trend: AZT has become profitable over the past 5 years, growing earnings by 65.9% per year.

Accelerating Growth: AZT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AZT had negative earnings growth (-22.9%) over the past year, making it difficult to compare to the Biotechs industry average (-15.9%).

Return on Equity

High ROE: AZT's Return on Equity (18.8%) is considered low.

Discover strong past performing companies

Financial Health

How is ArcticZymes Technologies's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: AZT's short term assets (NOK264.5M) exceed its short term liabilities (NOK18.5M).

Long Term Liabilities: AZT's short term assets (NOK264.5M) exceed its long term liabilities (NOK12.9M).

Debt to Equity History and Analysis

Debt Level: AZT is debt free.

Reducing Debt: AZT has not had any debt for past 5 years.

Debt Coverage: AZT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: AZT has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is ArcticZymes Technologies's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

ArcticZymes Technologies Dividend Yield vs Market
How does ArcticZymes Technologies dividend yield compare to the market?
SegmentDividend Yield
Company (ArcticZymes Technologies)n/a
Market Bottom 25% (NO)3.8%
Market Top 25% (NO)8.0%
Industry Average (Biotechs)2.2%
Analyst forecast in 3 Years (ArcticZymes Technologies)0%

Notable Dividend: Unable to evaluate AZT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AZT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AZT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AZT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AZT has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Jethro Holter (50 yo)





Dr. Jethro Holter has been Chief Executive Officer of ArcticZymes Technologies ASA (formerly known as Biotec Pharmacon ASA) since April 22, 2020. He was an Interim CEO at Biotec Pharmacon ASA since October...

CEO Compensation Analysis

Jethro Holter's Compensation vs ArcticZymes Technologies Earnings
How has Jethro Holter's remuneration changed compared to ArcticZymes Technologies's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021kr3mkr2m


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020kr2mkr2m


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019kr1mkr1m


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018kr2mkr1m


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017kr2mkr1m


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016kr2mkr1m


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015kr1mkr1m


Compensation vs Market: Jethro's total compensation ($USD255.15K) is below average for companies of similar size in the Norwegian market ($USD489.78K).

Compensation vs Earnings: Jethro's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: AZT's management team is considered experienced (2.9 years average tenure).

Board Members

Experienced Board: AZT's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: AZT insiders have only sold shares in the past 3 months.

Recent Insider Transactions

OB:AZT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Jul 22Sellkr168,830Volker WedershovenIndividual2,129kr79.30
10 Dec 21Sellkr10,560,000Jethro HolterIndividual120,000kr88.00

Ownership Breakdown

What is the ownership structure of AZT?
Owner TypeNumber of SharesOwnership Percentage
Public Companies568,0001.1%
Individual Insiders1,034,5562.1%
Private Companies6,140,87712.2%
General Public21,125,33341.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 54.8% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Skandinaviska Enskilda Banken AB, Private Banking, Investment Banking, and Insurance Arm
State Street Global Advisors, Inc.
2,599,996NOK184.6m6.08%no data
Nordnet AB (publ), Asset Management Arm
Avanza Fonder AB
Pro AS
2,005,216NOK142.4m0%no data
Joh. Berenberg, Gossler & Co. KG, Asset Management Arm
Danske Bank A/S, Asset Management Arm
Nikko Asset Management Co., Ltd.
1,213,637NOK86.2m0%no data
Belvedere AS
1,015,684NOK72.1m0%no data
Royal Bank of Canada, Banking & Securities Investments
Tellef Ormestad
848,162NOK60.2m-30.64%no data
SEB Investment Management AB
Middelboe AS
600,000NOK42.6m-0.3%no data
Norda ASA
568,000NOK40.3m0%no data
Didner & Gerge Fonder
Dragesund Invest AS
521,739NOK37.0m0%no data
KLP Kapitalforvaltning AS
DNB Asset Management AS
Avkast Invest AS
500,000NOK35.5m-12.06%no data
Coeli Asset Management
Naudholmen AS
461,000NOK32.7m0%no data
Handelsbanken Asset Management
324,301NOK23.0m0%no data
Ruffer LLP
Dimensional Fund Advisors LP
178,178NOK12.7m0.14%no data
J.P. Morgan Asset Management, Inc.
178,163NOK12.6m0%no data

Company Information

ArcticZymes Technologies ASA's employee growth, exchange listings and data sources

Key Information

  • Name: ArcticZymes Technologies ASA
  • Ticker: AZT
  • Exchange: OB
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr3.576b
  • Shares outstanding: 50.37m
  • Website:

Number of Employees


  • ArcticZymes Technologies ASA
  • Sykehusveien 23
  • SIVA Innovation Centre
  • Tromsø
  • Troms
  • 9294
  • Norway


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AZTOB (Oslo Bors)YesOrdinary SharesNONOKNov 2005
B4VDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2005
0DRVLSE (London Stock Exchange)YesOrdinary SharesGBNOKNov 2005
AZTOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKNov 2005

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/29 00:00
End of Day Share Price2022/09/29 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.